Core Viewpoint - The establishment of Shanghai Weinao Intelligent Technology Co., Ltd. marks a significant step in the strategic deployment of Xinwei Medical in the brain-computer interface (BCI) sector, transitioning from planning to practical implementation [1][2] Group 1: Company Developments - Xinwei Medical's subsidiary, Weinao Intelligent, has completed its business registration and is now located in the Shanghai Brain-Computer Interface Future Industry Cluster [1] - The company aims to focus on the research and clinical application of BCI technology, facilitating the transition from basic research to clinical treatment [1][2] - The establishment of Weinao Intelligent signifies a new phase of independent and specialized operations for Xinwei Medical in the BCI business [2] Group 2: Technological Innovations - The BCI project submitted by Xinwei Medical utilizes an innovative minimally invasive approach, implanting electrode stents into brain blood vessels without the need for craniotomy, significantly reducing surgical trauma [2] - This new method effectively avoids complications associated with traditional invasive surgeries, such as intracranial infections and long-term rejection reactions [2] - The intravascular electrodes can closely adhere to blood vessel walls, achieving a balance between high-quality neural signal acquisition and long-term stability [2] Group 3: Strategic Initiatives - Xinwei Medical's BCI project was selected for the 2025 Artificial Intelligence Medical Device Innovation Task, highlighting its strong innovation capabilities and potential for technology transfer [1] - The initiative aims to promote breakthroughs in AI medical devices and facilitate the practical application of products, with 16 BCI projects being selected [1]

港股脑机接口概念股再度活跃，其中，脑动极光大涨10%领衔，微创脑科学涨7.25%，南京熊猫电子涨 6.58%，脑洞科技涨3.56%，心玮医疗涨1.45%。 本文源自：金融界AI电报 ...

脑机接口板块持续走强，爱朋医疗20cm涨停创新高，南京熊猫此前涨停录得4连板，创新医疗、岩山科 技、塞力医疗涨幅居前。 ...

Group 1 - The core viewpoint of the news is that the brain-computer interface (BCI) sector is experiencing a surge in stock activity, driven by government support and industry events, with 2026 expected to be a pivotal year for commercialization [1][2] - The Ministry of Industry and Information Technology, along with eight other departments, has announced plans to accelerate the industrialization and commercialization of new terminal devices such as augmented reality/virtual reality (AR/VR) wearables and brain-computer interfaces [1] - The Brain-Computer Interface Industry Alliance and other organizations are set to hold the "2026 Brain-Computer Interface Developer Conference" in Tianjin on February 3-4, 2026, indicating a growing focus on this technology [1] Group 2 - Notable stock performances include Brain动极光 (up 9.85%), 微创脑科学 (up 7.25%), 南京熊猫电子 (up 6.58%), 脑洞科技 (up 3.56%), and 心玮医疗 (up 1.45%) [2] - The rapid increase in stock prices reflects a broader market enthusiasm for brain-computer interfaces, which were once considered a concept of science fiction but are now moving closer to reality [1]

Summary of the Conference Call for Xinwei Medical Company Overview - **Company**: Xinwei Medical - **Industry**: Brain-Computer Interface (BCI) and Neurointervention Key Points and Arguments Product Development and Technology - Xinwei Medical employs a minimally invasive endovascular approach to implant electrode stents via the internal jugular vein to capture motor cortex signals, reducing the risks associated with open brain surgery and improving signal stability. Animal experiments show stable signals even after 18 months [2][3] - The company plans to complete the registration application for its brain-computer interface product by 2028 and finish human clinical trials by 2027, with an expected recruitment of 30-50 patients for motor function recovery [2][4][5] - A collaboration with J.T. Medical aims to develop a new endovascular brain-computer interface that addresses the issue of electrode displacement in traditional invasive systems. Xinwei Medical is responsible for the design and development of the stent [2][6] Financial and Operational Aspects - Xinwei Medical anticipates having nearly 800 million yuan in cash by the end of 2025, with operating cash flow exceeding 100 million yuan, sufficient to cover the R&D costs of the brain-computer interface project, estimated at several tens of millions [3][17] - The estimated cost for mass production of the electrode stent is around 3,000-4,000 yuan, with total costs expected to remain under 10,000 yuan, potentially decreasing to a few thousand yuan in the future [9] Clinical Trials and Regulatory Pathway - The clinical trial plan is not fully finalized but is expected to follow a model similar to that of Boruikang, which conducted approximately 32 human experiments. The first patient recruitment is set to begin in the second half of this year [5][12] - The company is in communication with regulatory bodies to establish industry standards for the registration process, with patient recruitment expected to start in 2026 [14] Market and Competitive Landscape - The company aims to collaborate with leading consumer electronics companies like Huawei and Xiaomi to develop software functionalities for their products once the new indications are established [11] - The invasive brain-computer interface is designed for specific applications, primarily targeting patients with motor function impairments, with potential future applications in vision, language, and emotional control [10][22] Team and Resource Allocation - Xinwei Medical currently has a team of about 10 people focused on the brain-computer interface project, with plans to expand the team, particularly in signal decoding [8][7] - The company is actively seeking partnerships with software teams, universities, and research institutions to enhance its capabilities in software development [8] Future Outlook - The company is optimistic about the future of the brain-computer interface market, with a positive sentiment reflected in recent financing activities in the sector [16] - Xinwei Medical's neurointervention business is expected to grow at an annual rate of 30%-35% in the coming years, contributing to overall revenue growth [22] Challenges and Considerations - The main challenges in patient recruitment include ensuring safety and acceptance of the new technology among medical professionals and potential patients, particularly those with severe motor function impairments [12][18] - The company is preparing for potential overseas market entry, contingent on successful domestic registration and compliance with international regulations [20][21] Additional Important Information - The company is focused on optimizing its product, with static samples already available and dynamic samples expected to be showcased soon [13] - The reimbursement policies for invasive procedures are still being defined, with expectations that insurance coverage could reach 70%-80% once the product proves its safety and efficacy [15]

Market Overview - The A-share market opened lower with the Shanghai Composite Index down 0.20%, the Shenzhen Component down 0.42%, and the ChiNext Index down 0.63% [2][3] - Over 3,000 stocks declined in the market, with sectors such as brokerage, insurance, retail, and CPO experiencing significant drops [1] Sector Performance - The electronic gas sector saw a strong opening, with Sanfu Co. and Heyuan Gas hitting the daily limit up, while Jin Hong Gas, Huate Gas, Silane Technology, and Yake Technology also showed notable gains [1] - The brain-computer interface concept remained active, with companies like Prit and Innovation Medical achieving four consecutive trading limit ups [1] Notable Stocks - Zhongke Lanyun opened over 12% higher, projecting a net profit increase of 367%-377% year-on-year for 2025 [3] - Yijing Optoelectronics approached the daily limit down, announcing an expected negative net profit for the year 2025 [5] Hong Kong Market - The Hong Kong stock market opened lower, with the Hang Seng Index down 0.59% and the Hang Seng Tech Index down 0.44% [5][6] - Major stocks such as Tencent Music, Baidu Group, Alibaba, and Zijin Mining experienced significant declines, while China Shenhua, China Telecom, and China Merchants Bank showed strength [5]

消息面上，1月7日，工业和信息化部等八部门印发《"人工智能+制造"专项行动实施意见》，其中提 出，加速智能终端升级。聚焦工业巡检、远程医疗等重点场景，加快增强现实/虚拟显示(AR/VR)可穿戴 设备、脑机接口等新型终端的产业化、商业化进程。财信证券认为，脑机接口行业作为融合多学科前沿 技术的高成长赛道，在政策强力支持、医保支付落地与技术持续突破的驱动下，正迈向规模化应用关键 阶段。 国信证券指出，脑机接口已进入"技术突破向商业业化跃迁"的关键节点，锚定"政策+技术+场景"三重主 线。当前行业受益于"十五五"规划重点布局、医保赋码与医疗器械标准落地等政策红利，叠加Neuralik 量产预期与国内临床突破的催化，全球市场规模有望迎来爆发式增长。随着芯片、电极、算法等技术的 发展，法规标准的不断完善，预计未来几年脑机接口产品将迎来密集商业化。 脑机接口概念股多数上扬，截至发稿，脑洞极光-B(06681)涨7.91%，报7.78港元；微创脑科学(02172)涨 6.2%，报13.19港元；脑洞科技(02203)涨3.56%，报0.233港元。 ...

Group 1 - The core viewpoint of the article highlights the upward trend in brain-computer interface (BCI) concept stocks, driven by supportive government policies and technological advancements [1] - As of the report, notable stock performances include Brainhole Aurora-B (06681) up 7.91% to HKD 7.78, Micron Brain Science (02172) up 6.2% to HKD 13.19, and Brainhole Technology (02203) up 3.56% to HKD 0.233 [1] - The Ministry of Industry and Information Technology, along with eight other departments, issued the "Implementation Opinions on the Special Action of 'Artificial Intelligence + Manufacturing'" on January 7, focusing on accelerating the upgrade of smart terminals and emphasizing the industrialization and commercialization of new terminals like AR/VR devices and BCIs [1] Group 2 - Financial analysts believe that the BCI industry is entering a critical phase of scaling applications, supported by strong policy backing, the implementation of medical insurance payments, and continuous technological breakthroughs [1] - Guosen Securities indicates that the BCI sector is at a pivotal point of transitioning from technological breakthroughs to commercialization, driven by a combination of policies, technology, and application scenarios [1] - The industry is expected to benefit from the "14th Five-Year Plan" focus, medical insurance coding, and the establishment of medical device standards, alongside anticipated mass production of Neuralik and breakthroughs in domestic clinical applications, leading to explosive growth in the global market [1]

每经AI快讯，1月8日，脑机接口板块高开，创新医疗4连板创新高，爱朋医疗、南京熊猫、海南海药、 岩山科技、菲沃泰跟涨。 （文章来源：每日经济新闻） ...

Market Sentiment - The current market sentiment score is 78, indicating a "relatively hot" market condition, which suggests strong investor confidence [4][7][19]. Hot Themes Tracking - **Robotics Theme**: The establishment of a national standard organization for humanoid robots and embodied intelligence marks a transition from "technical exploration" to "industrial collaboration" and "scale implementation," which is expected to accelerate technology deployment and ecosystem formation. Related stocks include Sanhua Intelligent Control (002050) and Wolong Electric Drive (600580) [4]. - **Banking Theme**: Bank stocks exhibit high dividend characteristics, with the CSI Bank Index yielding 6.02%, significantly higher than the 10-year government bond yield. This makes bank stocks important investment targets for long-term funds like insurance and social security, especially during economic slowdowns. Related stocks include Agricultural Bank of China (601288) and Ningbo Bank (002142) [4]. - **Brain-Computer Interface Theme**: Neuralink plans to begin large-scale production of brain-computer interface devices in 2026, with a projected global market size of $12.4 billion by 2034 and a CAGR of 17% from 2025 to 2034. Related stocks include Apogee Medical (300753) and Maipu Medical (301033) [4]. Capital Flow Analysis - The top ten stocks with the highest net inflow include Aerospace Development (000547) with a net inflow of 193.34 million, Greenme (002340) with 126.57 million, and Northern Huachuang (002371) with 125.67 million [8]. - The top ten stocks with the highest net outflow include Leike Defense (002413) with a net outflow of -210.86 million, Haige Communication (002465) with -197.38 million, and Sanhua Intelligent Control (002050) with -192.55 million [10]. Industry Insights - The banking sector is highlighted for its stability and high dividend yield, making it a preferred choice for long-term investors during periods of economic uncertainty [4]. - The robotics industry is poised for significant growth due to the establishment of standards that will facilitate collaboration and reduce development costs, indicating a shift towards large-scale applications [4]. - The brain-computer interface market is expected to grow rapidly, driven by advancements in technology and increasing demand for innovative medical solutions [4].